Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The curvilinear relationships between grand parity and incidence of hormone-dependent cancers; follow-up of postmenopausal women in the Norwegian 1960 Census

View ORCID ProfileEiliv Lund, View ORCID ProfileLill-Tove Rasmussen Busund, View ORCID ProfileLars Holden
doi: https://doi.org/10.1101/2023.12.13.23299895
Eiliv Lund
1UiT The Arctic University of Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eiliv Lund
Lill-Tove Rasmussen Busund
2Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway
3Department of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lill-Tove Rasmussen Busund
Lars Holden
4Norwegian Computing Center, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lars Holden
  • For correspondence: lars.holden{at}nr.no
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Breast, ovarian and endometrial cancers are named hormone dependent cancers (HDC) because of the effects of endogenous hormones, including parity, on the incidence rates. Here, we will test the hypothesis that each additional child has the same relative preventive effect on the risk of each of the three cancer sites and with similar shapes of the incidence curves over the extended exposure range, 1 - 18 children in postmenopausal women.

The study is based on parity information from the Norwegian 1960 Census for women aged 45-89 years. A total of 385 816 married women answered the question of number of children in present marriage to a civil servant. Follow-up continued until the first of any of the HDC diagnosis, death, or end of follow-up 2005 through linkages based on the unique Norwegian birth number. Included were 16 905 breast cancers, 3 827 ovarian cancers and 3 834 endometrial cancers. Based on person-years (PY), the percentage change in incidence rates of the three cancer sites for each additional child was calculated using a logit regression model including models with higher order terms. A new statistical method for analyses of collinearity between parity and age at first birth has been developed. Age at marriage was used as a proxy for age at first birth.

Parity had strong linear effects on the incidence rates for all three cancer sites (p<2e-16). The percentage decrease for each of the cancer diagnosis for an additional child were for breast cancer 10.5% (95% CI; 9.6-11.4), ovarian cancer 13.2% (11.2-15.3) and endometrial cancer 10.9% (8.9-12.8) with similar curvilinear relationship. Models with higher order terms gave slightly better fit to the data with a stronger protective effect for increasing parity on ovarian cancers, while for breast cancer age became more important. Combining the incidence of all three cancers gave a percentage decrease for each additional child of 11.0% (10.1-11.8). The risk for HDC cancer was reduced with earlier age at marriage (first birth) for women with 1-2 children for breast cancer and ovarian cancer and 1 child for endometrial cancer, but the effect was smaller than one additional child. Age of the women at marriage was not significant for the sum of the three cancers.

The study demonstrated the strong, regular protective effect of each additional child or full-term pregnancy on the incidence rates of the hormone-dependent cancers throughout the exposure range and with similar curvilinear relations. Reduced fertility is a common, strong etiological factor for the three hormone-dependent cancers in postmenopausal women. These findings support a hypothesis that similar immunological changes during each pregnancy could be the biological explanation.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by a donation from Halfdan Jacobsen og frues legat (The Norwegian Cancer Society).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The project has been evaluated and accepted by the Regional Ethical Committee for South-East Norway (number 475656) and approved 12.10.2022.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • E-mail addresses:

    EL: eiliv.lund{at}uit.no;

    LB: Lill.Tove.Rasmussen.Busund{at}unn.no

    LH: Lars.Holden{at}nr.no

Data Availability

Most of the data is presented in the article. The complete data set has limitations due to privacy and only available in an application to Statistics Norway, Cancer Registry of Norway and Norwegian Institute of Public Health

  • Abbreviations

    HDC
    hormone-dependent cancer
    SMR
    standard mortality ratio
    OR
    odds ratio
    RR
    relative risk
    GM
    grand multiparity
    GGM
    grand-grand multiparity
    PY
    person years of follow-up
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted December 14, 2023.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    The curvilinear relationships between grand parity and incidence of hormone-dependent cancers; follow-up of postmenopausal women in the Norwegian 1960 Census
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    The curvilinear relationships between grand parity and incidence of hormone-dependent cancers; follow-up of postmenopausal women in the Norwegian 1960 Census
    Eiliv Lund, Lill-Tove Rasmussen Busund, Lars Holden
    medRxiv 2023.12.13.23299895; doi: https://doi.org/10.1101/2023.12.13.23299895
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    The curvilinear relationships between grand parity and incidence of hormone-dependent cancers; follow-up of postmenopausal women in the Norwegian 1960 Census
    Eiliv Lund, Lill-Tove Rasmussen Busund, Lars Holden
    medRxiv 2023.12.13.23299895; doi: https://doi.org/10.1101/2023.12.13.23299895

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Oncology
    Subject Areas
    All Articles
    • Addiction Medicine (427)
    • Allergy and Immunology (753)
    • Anesthesia (220)
    • Cardiovascular Medicine (3281)
    • Dentistry and Oral Medicine (362)
    • Dermatology (274)
    • Emergency Medicine (478)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
    • Epidemiology (13340)
    • Forensic Medicine (19)
    • Gastroenterology (897)
    • Genetic and Genomic Medicine (5130)
    • Geriatric Medicine (479)
    • Health Economics (781)
    • Health Informatics (3253)
    • Health Policy (1138)
    • Health Systems and Quality Improvement (1189)
    • Hematology (427)
    • HIV/AIDS (1014)
    • Infectious Diseases (except HIV/AIDS) (14613)
    • Intensive Care and Critical Care Medicine (910)
    • Medical Education (475)
    • Medical Ethics (126)
    • Nephrology (522)
    • Neurology (4901)
    • Nursing (261)
    • Nutrition (725)
    • Obstetrics and Gynecology (880)
    • Occupational and Environmental Health (795)
    • Oncology (2516)
    • Ophthalmology (722)
    • Orthopedics (280)
    • Otolaryngology (346)
    • Pain Medicine (323)
    • Palliative Medicine (90)
    • Pathology (540)
    • Pediatrics (1298)
    • Pharmacology and Therapeutics (548)
    • Primary Care Research (554)
    • Psychiatry and Clinical Psychology (4193)
    • Public and Global Health (7482)
    • Radiology and Imaging (1702)
    • Rehabilitation Medicine and Physical Therapy (1010)
    • Respiratory Medicine (979)
    • Rheumatology (478)
    • Sexual and Reproductive Health (495)
    • Sports Medicine (424)
    • Surgery (546)
    • Toxicology (71)
    • Transplantation (235)
    • Urology (203)